Press releases

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected mid-2021 Signature of an...

DEINOVE’s Boost-ID project has been selected as part of the “France Relance” plan, a recognition of its strategic positioning. Boost-ID is...

DEINOVE strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe gastrointestinal...

DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...

Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...

DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...

• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...

Significant achievements in antibiotic programs: Initiation of the Phase II trial testing DNV3837 as first-line treatment for severe C...

The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...